Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLORIA Study: Adagloxad Simolenin (OBI822)/OBI-821 in Adjuvant Treatment of High-Risk, Early-Stage Globo H-Positive Triple-Negative Breast Cancer
KCT0005816Phase 3Recruiting
- Sponsor
- OBI Pharma
- Start
- May 2021
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of adagloxad simolenin in breast cancer (2 arms), sponsored by OBI Pharma. Started May 2021; status: recruiting.
02
Drugs
adagloxad simolenin
03
Conditions
breast cancer
Beyond the preview
Go deeper on KCT0005816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005816.